• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

男性和女性家族性乳腺癌中的微小RNA表达谱分析

MicroRNA expression profiling in male and female familial breast cancer.

作者信息

Pinto R, De Summa S, Danza K, Popescu O, Paradiso A, Micale L, Merla G, Palumbo O, Carella M, Tommasi S

机构信息

IRCCS 'Giovanni Paolo II', Molecular Genetics Laboratory, Viale Orazio Flacco 65, Bari 70124, Italy.

IRCCS 'Giovanni Paolo II', Anatomopathology Unit, Bari, Italy.

出版信息

Br J Cancer. 2014 Dec 9;111(12):2361-8. doi: 10.1038/bjc.2014.535. Epub 2014 Nov 13.

DOI:10.1038/bjc.2014.535
PMID:25393370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4264445/
Abstract

BACKGROUND

Gender-associated epigenetic alterations are poorly investigated in male and female familial breast cancer (fBC). MicroRNAs may contribute to the different biology in men and women particularly related to RASSF1A pathways.

METHODS

Microarray technology was used to evaluate miRNA profile in 24 male and 43 female fBC. Key results were validated using RT-qPCR in an external samples set. In vitro studies were carried out to verify microRNA-target gene interaction.

RESULTS

Pathway enrichment analysis with the 287 differentially expressed microRNAs revealed several signalling pathways differently regulated in male and female cases. Because we previously hypothesised a peculiar involvement of RASSF1A in male fBC pathogenesis, we focussed on the MAPK and the Hippo signalling pathways that are regulated by RASSF1A. Male miR-152 and miR-497 upregulation and RASSF1A and NORE1A interacting gene downregulation were observed, confirming a possible indirect interaction between miRNAs and the two genes.

CONCLUSIONS

For the first time, a different microRNA expression pattern in male and female fBC has been shown. Moreover, the importance of RASSF1A pathway in male fBC carcinogenesis has been confirmed, highlighting a possible role for miR-152 and miR-497 in controlling MAPK and Hippo signalling pathways, regulated by RASSF1A.

摘要

背景

在男性和女性家族性乳腺癌(fBC)中,与性别相关的表观遗传改变研究较少。微小RNA可能导致男性和女性生物学差异,特别是与RASSF1A通路相关。

方法

利用微阵列技术评估24例男性和43例女性fBC中的miRNA谱。在外部样本集中使用RT-qPCR验证关键结果。进行体外研究以验证微小RNA-靶基因相互作用。

结果

对287种差异表达的微小RNA进行通路富集分析,发现男性和女性病例中几种信号通路的调控方式不同。由于我们之前假设RASSF1A在男性fBC发病机制中具有特殊作用,我们重点关注由RASSF1A调控的MAPK和Hippo信号通路。观察到男性miR-152和miR-497上调以及RASSF1A和NORE1A相互作用基因下调,证实了微小RNA与这两个基因之间可能存在间接相互作用。

结论

首次显示了男性和女性fBC中不同的微小RNA表达模式。此外,RASSF1A通路在男性fBC致癌作用中的重要性得到证实,突出了miR-152和miR-497在控制由RASSF1A调控的MAPK和Hippo信号通路中的可能作用。

相似文献

1
MicroRNA expression profiling in male and female familial breast cancer.男性和女性家族性乳腺癌中的微小RNA表达谱分析
Br J Cancer. 2014 Dec 9;111(12):2361-8. doi: 10.1038/bjc.2014.535. Epub 2014 Nov 13.
2
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.微小RNA与雌激素受体表达联合检测:家族性和散发性乳腺癌患者的新型分类方法
J Transl Med. 2014 Nov 19;12:319. doi: 10.1186/s12967-014-0319-6.
3
Different methylation and microRNA expression pattern in male and female familial breast cancer.男性和女性家族性乳腺癌中不同的甲基化和 microRNA 表达模式。
J Cell Physiol. 2013 Jun;228(6):1264-9. doi: 10.1002/jcp.24281.
4
Oral squamous cell carcinoma: microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism.口腔鳞状细胞癌:用于阐明肿瘤发生机制的微小RNA表达谱分析及综合分析
Mol Cancer. 2016 Apr 7;15:28. doi: 10.1186/s12943-016-0512-8.
5
Identification of differentially expressed microRNAs in human male breast cancer.鉴定人乳腺癌中差异表达的 microRNAs。
BMC Cancer. 2010 Mar 23;10:109. doi: 10.1186/1471-2407-10-109.
6
DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.DNA甲基化导致12种癌症相关微小RNA的失调及乳腺癌进展。
Gene. 2017 Mar 10;604:1-8. doi: 10.1016/j.gene.2016.12.018. Epub 2016 Dec 18.
7
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.微小RNA-125b的上调赋予芳香化酶抑制剂抗性,并且是乳腺癌预后不良的一个新标志物。
Breast Cancer Res. 2015 Jan 30;17(1):13. doi: 10.1186/s13058-015-0515-1.
8
MicroRNAs dysregulated in breast cancer preferentially target key oncogenic pathways.在乳腺癌中失调的微小RNA优先靶向关键致癌途径。
Mol Biosyst. 2011 Sep;7(9):2571-6. doi: 10.1039/c1mb05181d. Epub 2011 Jul 18.
9
miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.乳腺癌中的微小RNA表达随淋巴结转移及其他临床病理特征而变化。
IUBMB Life. 2014 May;66(5):371-7. doi: 10.1002/iub.1273. Epub 2014 May 20.
10
Reconstruction of temporal activity of microRNAs from gene expression data in breast cancer cell line.从乳腺癌细胞系的基因表达数据重建微小RNA的时间活性
BMC Genomics. 2015 Dec 18;16:1077. doi: 10.1186/s12864-015-2260-3.

引用本文的文献

1
Targeting Hippo signaling in cancer: novel perspectives and therapeutic potential.靶向癌症中的Hippo信号通路:新观点与治疗潜力
MedComm (2020). 2023 Oct 3;4(5):e375. doi: 10.1002/mco2.375. eCollection 2023 Oct.
2
Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer.Hippo 通路:癌症中的调控、失调及潜在治疗靶点。
Cancer Lett. 2021 Jun 1;507:112-123. doi: 10.1016/j.canlet.2021.03.006. Epub 2021 Mar 15.
3
The Unknown microRNA Expression of Male Breast Cancer. Similarities and Differences with Female Ductal Carcinoma. Their Role as Tumor Biomarker.

本文引用的文献

1
RASSF tumor suppressor gene family: biological functions and regulation.RASSF 肿瘤抑制基因家族:生物学功能与调控。
FEBS Lett. 2014 Aug 19;588(16):2671-84. doi: 10.1016/j.febslet.2014.02.041. Epub 2014 Mar 4.
2
Expression of microRNA-497 and its prognostic significance in human breast cancer.miR-497 在人乳腺癌中的表达及其预后意义。
Diagn Pathol. 2013 Oct 21;8:172. doi: 10.1186/1746-1596-8-172.
3
MicroRNA signatures in hereditary breast cancer.遗传性乳腺癌中的 microRNA 特征。
男性乳腺癌中未知微小RNA的表达。与女性导管癌的异同。其作为肿瘤生物标志物的作用。
J Cancer. 2018 Jan 1;9(3):450-459. doi: 10.7150/jca.23151. eCollection 2018.
4
Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer.微小RNA谱在预测人表皮生长因子受体2阳性乳腺癌患者新辅助化疗病理反应中的应用价值
Oncol Lett. 2017 Mar;13(3):1731-1740. doi: 10.3892/ol.2017.5628. Epub 2017 Jan 19.
5
miR-497 expression, function and clinical application in cancer.miR-497在癌症中的表达、功能及临床应用
Oncotarget. 2016 Aug 23;7(34):55900-55911. doi: 10.18632/oncotarget.10152.
6
Breast cancer intrinsic subtype classification, clinical use and future trends.乳腺癌内在亚型分类、临床应用及未来趋势。
Am J Cancer Res. 2015 Sep 15;5(10):2929-43. eCollection 2015.
7
Obesity and male breast cancer: provocative parallels?肥胖与男性乳腺癌:引人深思的相似之处?
BMC Med. 2015 Jun 4;13:134. doi: 10.1186/s12916-015-0380-x.
Breast Cancer Res Treat. 2013 Nov;142(1):19-30. doi: 10.1007/s10549-013-2723-7. Epub 2013 Oct 16.
4
MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer.miRNA-497 通过靶向 cyclin E1 调节乳腺癌细胞的生长和侵袭。
Cancer Cell Int. 2013 Oct 10;13(1):95. doi: 10.1186/1475-2867-13-95.
5
MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.基于 microRNA 的非 BRCA1/2 遗传性乳腺癌肿瘤的分子分类。
Br J Cancer. 2013 Nov 12;109(10):2724-34. doi: 10.1038/bjc.2013.612. Epub 2013 Oct 8.
6
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.癌症相关 miRNAs 的失调是良性和恶性人类乳腺肿瘤中的常见事件。
Carcinogenesis. 2014 Jan;35(1):76-85. doi: 10.1093/carcin/bgt333. Epub 2013 Oct 8.
7
RASSF1A Suppresses Cell Migration through Inactivation of HDAC6 and Increase of Acetylated α-Tubulin.RASSF1A 通过抑制 HDAC6 和增加乙酰化 α-微管蛋白来抑制细胞迁移。
Cancer Res Treat. 2013 Jun;45(2):134-44. doi: 10.4143/crt.2013.45.2.134. Epub 2013 Jun 30.
8
The microRNA-148/152 family: multi-faceted players.miRNA-148/152 家族:多面手。
Mol Cancer. 2013 May 19;12:43. doi: 10.1186/1476-4598-12-43.
9
The complex genetic landscape of familial breast cancer.家族性乳腺癌的复杂遗传景观。
Hum Genet. 2013 Aug;132(8):845-63. doi: 10.1007/s00439-013-1299-y. Epub 2013 Apr 5.
10
An update on male breast cancer and future directions for research and treatment.男性乳腺癌最新进展及研究与治疗的未来方向
Eur J Pharmacol. 2013 Oct 5;717(1-3):71-83. doi: 10.1016/j.ejphar.2013.03.037. Epub 2013 Mar 30.